Could Cannabis and / or Hemp Really Solve the Opioid Epidemic? What are the Patient Options

Phillip Zinni III, DO, FAOASM, MS, ATC Past-President; American Osteopathic Academy of Sports Medicine National Medical Director; The Industrial Athlete

Disclaimer: Associate of CTFO

Could Cannabis &/or Hemp Really Solve the Opioid Epidemic? What are the Patient Options: 1) Review the current prevalence and treatment of OA and MSK Inflammation 2) Review legislation that reduced/controlled narcotic prescriptions 3) Review the current use of Opioids for Pain 4) Learn what drove patients to seek alternative pain control 5) Learn the efficacy and safety of CBD

What Causes Musculoskeletal Pain?

Rapid Onset

Trauma
-Falls
-Injuries
-MVA

Insidious Onset
Overuse / Repetitive motion
Postural imbalance / strain
Poor Lifestyle

Symptoms & Types of Pain

Symptoms

- Sharp
- Severe
- Ache
- Burn
- Dull

Types

Acute
Chronic

Types of Pain

Acute

- Falls
 - Fractures
 - Dislocations
 - Injuries

MVA

- Work Related / Hobby
- Strain / Sprain

Chronic

- Overuse / Repetitive motion
 - Inflammatory
 - OA / Arthritis
 - Bursitis
 - Tendonitis
 - Non-Inflammatory
 - Tendinosis
- Postural imbalance / strain
 - Kyphosis
 - Lordosis

MSK Conditions

- Prevalence
 - Estimated 127M Americans (one in two adults)
 - comparable to total % Americans w/chronic lung or heart condition
 - Estimated \$213B annual treatment, care and lost wages
 - Arthritis and related conditions (66%)
 - Back and neck pain; injuries from falls, work, military service and sports (33%)

AAOS-2016

Related data/costs of musculoskeletal diseases & injuries:

- Arthritis and rheumatoid conditions resulted in an estimated 6.7 million annual hospitalizations.
- Average annual cost per person for treatment of a musculoskeletal condition is \$7,800.
 - Estimated annual cost for medical care to treat all forms of arthritis and joint pain was \$580.9 billion, which represented a 131 percent increase (in 2011 dollars) over 2000.
 - In 2012, 25.5 million people lost an average of 11.4 days of work due to back or neck pain, for a total of 290.8 million lost workdays in 2012 alone.

AAOS-2016

- **Osteoarthritis / Arthritis**
 - Prevalence
 - Arthritis most common joint disorder US
 - Knee OA 10% men & 13% women > 60 y/o



Consider "Arthritis in the Military"

- A Lifetime Of Disability for the rest of his or her life, require arthritis-related health care, paid for by U.S. taxpayers, in the form of doctor visits, medications, procedures and physical therapy.
- Average annual health care expenditures for a disabled veteran are \$7,450.
- Cost Example Based on a U.S. Army soldier diagnosed with post-traumatic OA at age 24 (two years after a traumatic injury), who is discharged and requires knee replacement surgery in his or her thirties. (Amounts will vary in individual situations, including the kind of treatment, surgery required, number of dependents, etc.)



Disability Compensation......\$494,722

LIFETIME TOTAL......\$976,172

Based on composite data from available resources, reports and calculations from the Center for Medicare Services and other national agencies.

Pain Management: Pharmaceuticals

Analgesia / Anti-Inflammatory

- Acetaminophens
- NSAIDS
 - Oral
 - Increased GI Side Effects
 - Topical
 - Decreased GI Side Effects

Sedative / Other

- zolpidem (Ambien)
- amitriptyline
- trazodone
- gabapentin (Neurontin)

Pain Management: Pharmaceuticals

Anti-Inflammatory

- NSAIDS
 - Topical Studies of diclofenac, ibuprofen & ketoprofen
 - Less Plasma concentrations
 - Increased Meniscus and Cartilage concentrations
 - Do NOT want this
- 1. C Rolf et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology 1999 38: 564-567.
- 2. CA Heyneman et al. Oral versus topical NSAIDs in rheumatic diseases. A comparison. Drugs 2000 60: 555-574.
- 3. J Radermacher et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. British Journal of Clinical Pharmacology 1991 31: 537-541.

What are Treatment Options for **Musculoskeletal Pain? Complementary and Traditional**

- **Pharmaceutical**
- **Manipulation**
- **Physical Therapy**

Alternative

- Acupuncture
- **Body Alignment Therapy**
- Dietary •
 - Herbal
- **Homeopathic**
- Massage •
- **Mind-Body Therapy**
- **Viscosupplementation Inj** •
- **Prolotherapy** •
- PRP
- **Stem Cell**

Biologic Therapy

Pain Management: Pharmaceuticals

#1) What about Steroid Injections?

✓ Steroids if individual will NOT out live their joint or body part (PZ).

✓ Jüni P Intra-articular corticosteroid for knee osteoarthritis.
 Cochrane Database Syst Rev. Oct. 2015
 Unclear if clinically important benefits of intra-articular corticosteroids after one to six weeks, effects decrease over time, and no evidence that an effect remains six months after a corticosteroid injection.

 Wernecke C, The Effect of Intra-articular Corticosteroids on Articular Cartilage: A Systematic Review. Orthop J Sports Med. Apr. 2015
 Corticosteroids have a time- and dose-dependent effect on articular cartilage, with detrimental effects at high doses and durations.

 Bellamy N IA corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. Apr. 2006
 Longer term benefits have not been confirmed based on the RevMan analysis. The response to HA products appears more durable.

Pain Management: Pharmaceuticals

#2) What about Viscosupplementation Injection? (AMSSM Position Statement)

- Knee OA with viscosupplementation injection [hyaluronic acid (HA)] vs. steroid [intra-articular corticosteroid (IAS)] vs. placebo [intraarticular placebo (IAP)] treatment effect using Outcome Measures in Rheumatoid Arthritis Clinical Trials–Osteoarthritis Research Society International (OMERACT-OARSI) criteria.
- Systematic literature search relevant articles 1960 to August 2014 in the MEDLINE, EMBASE, and Cochrane CENTRAL using a network meta-analysis (NMA) of relevant literature determine a benefit from HA vs. IAS vs. IAP.
- 11 articles met inclusion criteria from the search strategy.
 Subjects receiving HA were 15% and 11% more likely to respond to treatment by the OMERACT-OARSI criteria than those receiving IAS or IAP, respectively (*P* < 0.05 for both).
 Recommends HA for the appropriate patients with knee OA.

Pain Management: Regenerative Medicine #3) What is Prolotherapy?

- Nonsurgical treatment
- Strengthen and tighten the ligaments and tendons
 - that hold bones and muscles in place.
- Series of injections stimulate body's natural healing response
- Restores proper joint alignment and relieves pressure on sensitive tissues.
- > Dramatic and lasting pain relief.

Pain Management: Regenerative Medicine #4) PRP (Concentrated Platelets) = Platelet Rich Plasma How Does PRP Injection Work?

- Injections of concentrated platelets with growth factors and low or high leukocyte concentrations into the damaged area.
- Triggers and provides the body's natural healing response and causes the proliferation of new tissue of ligaments, tendons or chondral surface.
- Tissue growth continues, the ligaments and tendons become thicker and stronger, regaining their ability to stabilize the joint and take the pressure off sensitive nerve endings.
- Pain subsides, range of motion returns, and cartilage degeneration slows down, halts or reverses.
- Sometimes one treatment is enough to achieve complete pain relief, but it usually takes 3 treatments, administered at 3-5 weeks apart, to produce sufficient tissue growth to relieve pain and restore normal function.

Pain Management: Regenerative Medicine #5) What's an MSC?

- Mesenchymal stem cell
 - Present in adipose and orthopedic tissues like bone, periosteum, synovial tissue, cartilage, bone marrow, muscle, ligaments, and tendon
- Can differentiate into all orthopedic tissues and orchestrate repair of same



Could Cannabis &/or Hemp Really Solve the Opioid Epidemic? What are the Patient Options: 1) $\sqrt{Review the current prevalence and}$ treatment of OA and MSK Inflammation Abnormal forces, environment / lifestyle. Review legislation that reduced/controlled narcotic prescriptions 2) Review the current use of Opioids for Pain 3)

4) Learn what drove patients to seek alternative pain control

5) Learn the efficacy and safety of CBD



Could Cannabis &/or Hemp Really Solve the Opioid Epidemic? What are the Patient Options:

- Neview the current prevalence and treatment of OA and MSK Inflammation
- 2) \langle Review legislation that reduced/controlled narcotic prescriptions

Review the current use of Opioids for Pain
 Learn what drove patients to seek alternative pain control
 Learn the efficacy and safety of CBD

Legislation that Reduced/Controlled Narcotic Prescriptions

The Law: Controlled Substance Abuse Prevention Act (Assembly Bill 474) – January 1, 2018

The Basics:

- 1) Two units of CME per licensing cycle required for all licensed prescribers
- 2) Mandated Registry and Use of PMP:
 - Every initial Prescription and every 90 days during course of treatment.
 - All licensed prescribers must self-query every 6 months.
- 3) New Prescriptions Requirements:
 - All RXs for Controlled Substances must include: Patient's DOB, ICD-10 code, minimum number of days to consume the prescribed medication, prescriber's DEA license must be clearly identified.
- 4) Prescribing Guidelines for Controlled Substances.
 - CDC Guideline for Prescribing Opioids for Chronic Pain, 2016
- 5) Overdose Reporting

CDC cares about the health, safety, and well-being of patients with chronic pain. CDC is committed to ensuring that these patients get the best possible care. There is not enough science to know whether opioids control chronic pain long term, but it is clear that they have very serious risks and side effects.



As many as 1 in 4

patients receiving long-term opioid therapy in primary care settings



struggle with opioid use disorder.

The Epidemic

The United States is in the midst of an epidemic of prescription opioid overdoses. The amount of opioids prescribed and sold in the US quadrupled since 1999, but the overall amount of pain reported by Americans hasn't changed. This epidemic is devastating American lives, families, and communities.



More than 40 people die every day from overdoses involving prescription opioids.¹



Since 1999, there have been over 165,000 deaths from overdose related to prescription opioids.¹

4.3 million Americans engaged in non-medical use of prescription opioids in the last month.²

CDC Recommendations to Manage Pain

Consider ways to manage chronic pain without prescription opioids. Some options may work better and have fewer risks and side effects:



Legislation that reduced/controlled narcotic prescriptions

4) Prescribing Guidelines for Controlled Substances.

CDC Guideline for Prescribing Opioids for Chronic Pain, 2016

The *Guideline for Prescribing Opioids for Chronic Pain* was developed because CDC recognized that providers need current recommendations for prescribing opioids to improve pain management and patient safety. The guideline and corresponding clinical tools help providers and patients:

3

ASSESS. Assess the risks and benefits of using opioids for chronic pain.

DISCUSS.

Set realistic goals for pain and function and make informed decisions about starting or continuing opioid therapy.

CONSIDER.

Exercise caution and consider the safest and most effective treatments for pain.

MONITOR.

4

Follow-up regularly to reassess progress and consider how opioid therapy will be discontinued if benefits do not outweigh risks.

Legislation that reduced/controlled narcotic prescriptions

4) Prescribing Guidelines for Controlled Substances.

- Guideline Developed to:
 - Improve communication between clinicians and patients about the benefits and risks of using prescription opioids for chronic pain
 - Provide safer, more effective care for patients with chronic pain
 - Help reduce opioid use disorder and overdose

Legislation that reduced/controlled narcotic prescriptions

5) Overdose Reporting

Who is required to report? Per Nevada Administrative Code (NAC)441A. 100, a "provider of healthcare" means a physician, nurse or veterinarian licensed in accordance with state law or a physician assistant licensed pursuant to Nevada Revised Statutes (NRS) Chapter 630 or 633

Full details:

http://dpbh.nv.gov/uploadedFiles/dpbhnvgov/content/Resources/opioids/NV-Overdose-Report-FAQ.pdf

http://dpbh.nv.gov/Resources/opioids/Prescription_Drug_Abuse_Prevention/



Could Cannabis &/or Hemp Really Solve the Opioid Epidemic? What are the Patient Options:

- √ Review the current prevalence and treatment of OA and MSK Inflammation
- 2) Review legislation that reduced/controlled narcotic prescriptions
 3) Review the current use of Opioids for Pain
- 4) Learn what drove patients to seek alternative pain control5) Learn the efficacy and safety of CBD

The current use of Opioids for Pain

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Checklist for prescribing opioids for chronic pain

For primary care providers treating adults (18+) with chronic pain ≥3 months, excluding cancer, palliative, and end-of-life care

CHECKLIST

When CONSIDERING long-term opioid therapy

- Set realistic goals for pain and function based on diagnosis (eg, walk around the block).
- □ Check that non-opioid therapies tried and optimized.
- □ Discuss benefits and risks (eg, addiction, overdose) with patient.
- Evaluate risk of harm or misuse.
 - Discuss risk factors with patient.
 - Check prescription drug monitoring program (PDMP) data.
 - · Check urine drug screen.
- □ Set criteria for stopping or continuing opioids.
- □ Assess baseline pain and function (eg, PEG scale).
- □ Schedule initial reassessment within 1–4 weeks.
- Prescribe short-acting opioids using lowest dosage on product labeling; match duration to scheduled reassessment.

If RENEWING without patient visit

REFERENCE

EVIDENCE ABOUT OPIOID THERAPY

- Benefits of long-term opioid therapy for chronic pain not well supported by evidence.
- Short-term benefits small to moderate for pain; inconsistent for function.
- Insufficient evidence for long-term benefits in low back pain, headache, and fibromyalgia.

NON-OPIOID THERAPIES

Use alone or combined with opioids, as indicated:

- Non-opioid medications (eg, NSAIDs, TCAs, SNRIs, anti-convulsants).
- Physical treatments (eg, exercise therapy, weight loss).
- Behavioral treatment (eg, CBT).
- Procedures (eg, intra-articular corticosteroids).

EVALUATING RISK OF HARM OR MISUSE

Known risk factors include:

 Illegal drug use; prescription drug use for nonmedical reasons.

The current use of Opioids for Pain

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 Chronic pain = lasts >3 months or past the time of normal tissue healing (5).

- 1999–2002 National Health and Nutrition Examination Survey
 14.6% adults widespread or localized pain lasting at least 3 months.
- 2001–2003 Survey: Overall prevalence of common, predominantly musculoskeletal pain conditions (e.g., arthritis, rheumatism, chronic back or neck problems, and frequent severe headaches) estimated 43% adults in the US,
- 2012 National Health Interview: 11.2% adults report daily pain.
- Evidence supports short-term efficacy of opioids for reducing pain and improving function in noncancer nociceptive and neuropathic pain in randomized clinical trials lasting primarily ≤12 weeks.
- Few studies conducted to rigorously assess the long-term benefits of opioids for chronic pain (pain lasting >3 months) with outcomes examined at least 1 year later.



Could Cannabis &/or Hemp Really Solve the Opioid Epidemic? What are the Patient Options:

-) √ Review the current prevalence and treatment of OA and MSK Inflammation
- 2) √ Review legislation that reduced/controlled narcotic prescriptions
 3) √ Review the current use of Opioids for Pain
- 4) √ Learn what drove patients to seek alternative pain control
- 5) Learn the efficacy and safety of CBD

What drove patients to seek alternative pain control PCP Perspective

- 1) Onerous guidelines
 - a) **PMP** Monitoring
 - b) Drug Testing
 - c) Paperwork
- 2) Threat of losing license
 - a) Regulations and guidelines contribute to the paranoia
- 3) Increased referral rate to Pain Management
 - a) Bottle neck / delay to be seen
- 4) 2018 Farm Bill, according to FDA made any cannabis or cannabis derivates with less than 0.3 percent THC no longer a "controlled substance." This applies to most CBD products.

Patients seek alternative pain control

Survey data from patrons of Michigan medical marijuana dispensary suggesting that medical cannabis use in pain patients was associated with a 64% reduction in opioid use (Boehnke et al., 2016).

Prescription data from Medicare Part D enrollees in states with medical access to cannabis suggest a significant reduction in the prescription of conventional pain medications (<u>Bradford and Bradford, 2016</u>).

Pain is one of the primary reasons for the use of medical cannabis, suggest a number of pain patients are replacing the use of opioids with cannabis, despite the fact that cannabis has not been approved by the FDA for chronic pain. Ch. 4 Therapeutic Effects of Cannabis and Cannabinoids https://www.ncbi.nlm.nih.gov/books/NBK425767/

Patients seek alternative pain control

"CBD may be able to treat addiction through reduced activation of the amygdala during negative emotional processing and has been found to reduce heroin-seeking behavior, likely through its modulation of dopamine and serotonin." <u>43</u>, <u>44</u>, <u>85</u>, <u>86</u>

"An attractive option in chronic pain treatment, particularly in the context of opioid abuse, not only because of its potential efficacy but also because of its limited misuse and diversion potential as well as safety profile." ⁸⁶

https://www.mayoclinicproceedings.org/article/S0025-6196(19)30007-2/fulltext

Patients seek alternative pain control

"More research will be needed because these were pilot human studies with small sample sizes, but they represent potential future areas of cannabinoid use in the clinical treatment of pain relief and opioid abuse."

"More reflection on the right political and industrial means to go about expanding access to CBD is needed in the context of controversial evidence supporting expanding access to medical marijuana as a pain control option." $\underline{6}$, $\underline{86}$

https://www.mayoclinicproceedings.org/article/S0025-6196(19)30007-2/fulltext



Could Cannabis &/or Hemp Really Solve the Opioid Epidemic? What are the Patient Options:

- √ Review the current prevalence and treatment of OA and MSK Inflammation 2) 3)
 - √ Review legislation that reduced/controlled narcotic prescriptions \sqrt{Review} the current use of Opioids for Pain √ Learn what drove patients to seek alternative pain control
 - √ Learn the efficacy and safety of CBD

4)

Solution States Stat

"The 1st ever controlled trial of a CBM (Cannabis Based Medicine) in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following nabiximols (Sativex) treatment. While the differences are small and variable across the population, they represent benefits of clinical relevance and show the need for more detailed investigation in this indication."

Pain Management: CBD CBDA as a selective cyclooxygenase-2 inhibitory component in cannabis - 2008

Takeda S¹, Misawa K, Yamamoto I, Watanabe K.

Organization for Frontier Research in Preventive Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.

- Cannabidiolic acid (CBDA) selectively inhibited cyclooxygenase (COX)-2 activity having 9-fold higher selectivity than COX-1 inhibition.
- The carboxylic acid moiety in CBDA is a key determinant for the inhibition.
- The crude extract of cannabis containing mainly CBDA was shown to have a selective inhibitory effect on COX-2.
- This study suggest that naturally occurring CBDA in cannabis is a selective inhibitor for COX-2.

Cannabinoids in the management of difficult to treat pain <u>Ther Clin Risk Manag</u>. 2008 <u>Ethan B Russo</u>

"Given (cannabinoids) multi-modality effects upon various nociceptive pathways, their adjunctive side benefits, the efficacy and safety profiles to date of specific preparations in advanced clinical trials, and the complementary mechanisms and advantages of their combination with opioid therapy, the future for cannabinoid therapeutics appears very bright, indeed."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/

Cannabinoids as novel anti-inflammatory drugs

Executive summary

- Cannabinoids, mediate their effects through activation of specific cannabinoid receptors known as cannabinoid receptor 1 and 2 (CB1 and CB2).
- Cannabinoid system has been shown both *in vivo* and *in vitro* to be involved in regulating the immune system through its immunomodulatory properties.
- Cannabinoids suppress inflammatory response and subsequently attenuate disease symptoms. This property of cannabinoids is mediated through multiple pathways such as suppression of cytokines and chemokines at inflammatory sites.
- Cannabinoids have been tested in several experimental models of autoimmune disorders such as rheumatoid arthritis and have been shown to protect the host from the pathogenesis through induction of multiple anti-inflammatory pathways.

Prakash Nagarkatti; Future Med Chem. 2009 Oct; 1(7): 1333–1349. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828614/

Pain Management: CBD CBDa, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration, Takeda, et.al., 2012 "These results indicate that COX-2 activity is " not an essential factor for the migration of MDA-MB-231 cells, and that other pathway(s) are likely to be involved in the anti-migration effects of CBDA." ✓ How relates to MSK Pain? **CBDa activity does NOT affect regenerative** pathways of tissue growth and repair factors (PRP, MSC)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009504/

Involvement of the endocannabinoid system in osteoarthritis pain La Porta C, et.al., 2014

"The ubiquitous distribution of cannabinoid receptors, together with the physiological role of the endocannabinoid system in the regulation of pain, inflammation and even joint function further support the therapeutic interest of cannabinoids for osteoarthritis... This review summarizes the promising results that have been recently obtained in support of the therapeutic value of cannabinoids for osteoarthritis management."

Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids <u>MelissaO'Brien</u>, 2016

- Cannabis used for millennia to treat a multitude of medical conditions including chronic pain.
- OA pain one of most common types pain and patients turning cannabis to manage their symptoms.
- Growing body of scientific evidence supporting analgesic potential of cannabinoids to treat OA pain.
- ✓ An <u>endocannabinoid system</u> identified in OA joints.
- Animal studies show <u>cannabinoids</u> reduce OA pain, inflammation and nerve damage.
- ✓ Few clinical trials tested efficacy/safety medical cannabis.
- Endocannabinoid system looks promising for OA pain, but more research is required.

https://www.sciencedirect.com/science/article/pii/S1471489218300043?via%3Dihub

- ✤ Few contraindications similar as CYP450 enzyme pathway.
- Philpott "Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis" Pain, 2017 Dec, NIH Database "Showed 1st time local CBD administration inhibited pain & peripheral sensitization in established OA. Topical treatment with CBD reduced leukocyte trafficking and joint hyperemia during the early stages of MIA (*Joint irritant*). By attenuating this initial inflammatory response with CBD, end-stage OA pain and peripheral neuropathy were abrogated. Thus, CBD may be a safe therapeutic to treat OA pain locally as well as block the acute inflammatory flares that drive disease progression and joint neuropathy."
- * Hammell "Transdermal cannabidiol reduces inflammation and pain-related behaviors in a rat model of arthritis" Eur J Pain. 2016 NIH Database "These studies demonstrate topical applied CBD has long-lasting therapeutic effects w/o psychoactive side-effects. Thus, topical CBD has potential as effective treatment of arthritic symptomatology. At present, one in five (21%) adults worldwide are diagnosed with some form of arthritis by their physicians (Helmick et al., 2008). The data presented suggest transdermal CBD is a good candidate for developing improved therapies for these debilitating disease."

- The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research - 2017
 - ✓ The committee reached nearly 100 research conclusions based on consideration of more than 10,000 research articles
 - The committee found three medical applications for cannabis use supported by conclusive evidence:
 - 1. In adults with chemotherapy induced nausea and vomiting, oral cannabinoids are effective antiemetics.
 - **2.** In adults with chronic pain, patients who were treated with cannabis or cannabinoids are more likely to experience a clinically significant reduction in pain symptoms
 - 3. In adults with multiple sclerosis (MS) related spasticity, short term use of oral cannabinoids improves patient-reported spasticity symptoms.
 - For these conditions the effects of cannabinoids are modest; for all other conditions evaluated there is inadequate information to assess their effects.

http://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/201 7/Cannabis-Health-Effects/Cannabis-public-release-slides.pdf

Pain Management: CBD CBD Oil

Should You Try It for Arthritis Symptoms? - 2019

Daniel Clauw, MD, Professor University of Michigan, an expert in chronic pain, doesn't write off CBD's potential benefits and recommends it to some of his patients.

"A recent trial showed CBD alone was effective in [the treatment of] knee OA, and it appears as though it is very safe," he says. "Nearly all potential side effects of cannabinoids are from THC, not CBD." https://www.arthritis.org/living-with-arthritis/treatments/natural/supplementsherbs/cannabidiol-oil.php

Summaries from the NFL/NFLPA Committee on Pain Management: 1) Alternatives to Opioids for Chronic Pain and 2) Cannabidiol and Cannabis - 2019

ALT-O: Alternatives to Opioids for Chronic Pain

State of the Science: Cannabidiol (CBD) and Cannabis

Players may see CBD and medical cannabis as possible solutions to their medical issues— especially pain-related issues—but the state of the science is complicated.

Players may opt for CBD as a medical treatment in lieu of treatments with more scientific evidence supporting them.

Raphael Mechoulam, Ph.D., Professor Hebrew University of Jerusalem Head, Medicinal Chemistry Lab President, Multidisciplinary Center for Cannabinoid Research Head of Research for EPM

The Chemistry Behind Cannabinoid Acid – 2019

"CBDA, it is naturally occurring but very unstable, and is much stronger than CBD with no side effects.....the activities of these acids and they seem to be important and very important particularly in a variety of fields."

https://www.healtheuropa.eu/raphael-mechoulam-latestfindings-93683-2/93683/



While Americans were getting high, groovin' to the Beatles and winning the space race to the moon, a research scientist on the other side of the world, in Israel, discovered and literally named the compounds known as cannabinoids. Today the most known are THC and CBD.

But, according to this doctor, Dr. Mechoulam, there is a parent cannabinoid of CBD that is about to grab all the headlines – CBDa.

Pain Management: CBD What is a good starting dose? *Start low and go slow! (I don't Rx THC) *Usual starting dose of CBD 0.1-0.6 mg/kg in 1-2 divided doses, up to 10-20mg/kg. 150 lb - 7 to 12 mg up to 78 to 156 mg 180 lb – 17mg ie 5mg/kg *Different delivery methods have different onset and duration times - be aware (oral ingested delayed vs. sublingual faster acting) - unsure on transdermal



Thank you for your time and care of patients!

Phillip Zinni III, DO, FAOASM, MS, ATC

Past-President
American Osteopathic Academy of Sports Medicine

National Medical Director The Industrial Athlete

209-324-2255 JockOccDoc@Hotmail.com

Form Follows Function or Deformity Delineates Dysfunction

SANS – Christopher Centeno MD









Form Follows Function or Deformity Delineates Dysfunction



BIOTENSEGRITY Buckyball / Buckminsterfullerene Organism approach states everything is in balance even at the cellular level.

Pain Management: Herbal

Daily Doses

- Boswellia Serrata Extract:
- Curcumin Extract (Turmeric):
- Cayenne:
- Devil's Claw:
- Feverfew
- Ginger:
- White Willow Bark (Salicin):

1200 mg 1200 mg 360-2400 mg 1530 mg 85-125 mg 1200 mg 360-720 mg